Table 2.
Univariate and multivariate analyses of prognostic factors in NPC
| Variable | Univariate analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| OS | DFS | OS | DFS | |||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age, <55 vs. ≥55 | 5.151 (2.423-10.950) | <0.001** | 2.752 (1.484-5.105) | 0.001** | 3.399 (1.438-8.030) | 0.005** | 1.703 (0.840-3.453) | 0.140 |
| Gender, male vs. female | 0.637 (0.292-1.391) | 0.258 | 0.699 (0.345-1.415) | 0.319 | 0.340 (0.147-0.786) | 0.012* | 0.422 (0.198-0.902) | 0.026* |
| T stage, T1-2 vs. T3-4 | 1.378 (0.729-2.606) | 0.323 | 1.387 (0.767-2.508) | 0.279 | 1.864 (0.867-3.017) | 0.111 | 1.125 (0.550-2.301) | 0.747 |
| N stage, N0 vs. N1-3 | 1.000 (0.440-2.271) | 0.999 | 0.739 (0.365-1.496) | 0.401 | 0.933 (0.289-3.017) | 0.908 | 0.391 (0.144-1.063) | 0.066 |
| Clinical stage, I-II vs. III-IV | 1.652 (0.690-3.954) | 0.259 | 1.692 (0.753-3.798) | 0.203 | 2.653 (0.616-11.428) | 0.190 | 7.125 (1.809-28.068) | 0.005** |
| p53 expression, low vs. high | 1.105 (0.486-2.513) | 0.811 | 1052 (0.489-2.264) | 0.897 | 0.978 (0.399-2.401) | 0.962 | 1.036 (0.440-2.441) | 0.935 |
| Ki-67 expression, low vs. high | 0.900 (0.469-1.730) | 0.753 | 0.699 (0.374-1.307) | 0.262 | 0.710 (0.338-1.491) | 0.365 | 0.676 (0.334-1.369) | 0.277 |
| EBER expression, low vs. high | 1.166 (0.455-2.992) | 0.749 | 1.307 (0.513-3.325) | 0.575 | 0.742 (0.268-2.054) | 0.565 | 0.892 (0.330-2.410) | 0.821 |
| PABPC1 expression, low vs. high | 6.788 (2.837-16.244) | <0.001** | 3.889 (1.964-7.702) | <0.001** | 5.376 (2.110-13.694) | <0.001** | 3.311 (1.580-6.940) | 0.002** |
| Treatment, no vs. yes | 0.137 (0.071-0.262) | <0.001** | 0.176 (0.097-0.319) | <0.001** | 0.097 (0.043-0.215) | <0.001** | 0.092 (0.043-0.197) | <0.001** |
| Drugs, Docetaxel vs. Paclitaxel | 0.473 (0.153-1.463) | 0.194 | 0.894 (0.342-2.338) | 0.820 | 0.841 (0.228-3.099) | 0.794 | 1.768 (0.586-5.332) | 0.312 |
| Combination, Paclitaxel + PABPC1 low-expression vs. other regimens | 7.305 (0.941-56.716) | 0.057 | 1.542 (0.546-4.351) | 0.414 | 4.117 (0.394-43.028) | 0.237 | 1.112 (0.231-5.350) | 0.895 |
NPC Nasopharyngeal carcinoma, HR Hazard ratio, CI Confidence interval, OS Overall survival, DFS Disease-free survival
* and **, P value < 0.05 and 0.01 were used to determine whether differences were statistically significant between the two compared groups.